Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis

Journal of Chemotherapy

Volumn 22, Issue 6, 2010, Pages 384-391

  Redman, R ^a   Damiao, R ^b   Kotey, P ^a   Kaniga, K ^a   Davies, T ^a   Naber, K G ^c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Doripenem; E. coli; Levofloxacin; Pyelonephritis; Urinary tract infections

Indexed keywords

DORIPENEM; LEVOFLOXACIN; CARBAPENEM DERIVATIVE; OFLOXACIN; URINARY TRACT ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIURIA; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEVER; HEADACHE; HUMAN; INSOMNIA; KLEBSIELLA PNEUMONIAE; NAUSEA; OUTCOME ASSESSMENT; PHLEBITIS; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; VOMITING; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENETICS; GENOTYPE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROBIOLOGY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTI-INFECTIVE AGENTS, URINARY; CARBAPENEMS; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OFLOXACIN; PYELONEPHRITIS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 79958280592     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.6.384     Document Type: Article

References (12)

1. Orenstein R, Wong ES. Urinary tract infections in adults. Am Family Phys 1999; 59(5): 1225-1234.
2. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 2003; 49(2): 71-82.
3. Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opin Investig Drugs 2002; 11(4): 529-544.
4. Doripenem for injection [package insert], Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2009.
5. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005; 11(12): 974-984.
6. Wagenlehner FM, Naber KG. Treatment of bacterial urinary tract infections: presence and future. Eur Urol 2006; 49(2): 235-244.
7. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009; 53(9): 3782-3792.
8. CLSI. (Clinical and Laboratory Standards Institute). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard-7th ed. Wayne, PA 19087 1898 USA: CLSI; 2006.
9. Tenover FC, Arbeit, RD, Goering RV, Miokelsen PA, Murray BE, Pers-ing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33(9): 2233-2239.
10. Jimenez-Cruz F, Jasovich A, Cajigas J, Jiang Q, Imbeault D, Woods GL, et al; Protocol 021 Study Group. A prospective, multicenter, random- ized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology 2002; 60(1): 16-22.
11. Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, et al; Protocol 014 Study Group. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother 2002; 46(9): 2895-2900.
12. Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother 2001; 45(5): 1402-1406.